Louis P Lacasse insider trades: Conatus Pharmaceuticals (CNAT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Louis reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 30, 2013 | CNAT | ↑ Buy | 123,950 | $11.00 | $1.4M | Indirect | Aug 1, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Louis P Lacasse's insider trades
Louis P Lacasse is a director at Conatus Pharmaceuticals (CNAT). Since Jul 30, 2013, Louis has reported 1 open-market purchase worth $1.4M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), conversions (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CNAT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.